Skip to main content
Top

26-04-2016 | Genitourinary cancers | Book chapter | Article

6. Docetaxel in Advanced and Castration Resistant Prostate Cancer

Authors: Daniel P. Petrylak, Navid Hafez

Publisher: Springer International Publishing

Abstract

In 2004, two randomized trials demonstrated that docetaxel based therapy had superior survival in castrate resistant metastatic disease when compared to the then standard of care, mitoxantrone combined with corticosteroids. Today, docetaxel, along with fellow taxane cabazitaxel, remain the primary chemotherapeutic agents in metastatic castrate resistant prostate cancer. This chapter will summarize the mechanisms of docetaxel efficacy and resistance in prostate cancer, review the data for docetaxel use in metastatic castrate resistant disease including data on docetaxel in combination with other agents, and highlight the emerging role for docetaxel in hormone sensitive metastatic and local disease.
Literature
1.
Eisenberger MA, Simon R, O’Dwyer PJ, et al. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol: official J Am Soc Clin Oncol. 1985;3:827–41.
2.
Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 1993;71:1098–109.CrossRefPubMed
3.
Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet. 1999;36:99–114.CrossRefPubMed
4.
Ganju A, Yallapu MM, Khan S, et al. Nanoways to overcome docetaxel resistance in prostate cancer. Drug Resist Updates: Rev Commentaries Antimicrob Anticancer Chemother. 2014;17:13–23.CrossRef
5.
Monegier B, Gaillard C, Sablé S, et al. Structures of the major human metabolites of docetaxel (RP 56976—Taxotere®). Tetrahedron Lett. 1994;35:3715–8.CrossRef
6.
Royer I, Monsarrat B, Sonnier M, et al. Metabolism of docetaxel by human cytochromes P450: Interactions with paclitaxel and other antineoplastic drugs. Cancer Res. 1996;56:58–65.PubMed
7.
Kruijtzer CM, Beijnen JH, Schellens JH. Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: An overview. oncologist. 2002;7:516–30.CrossRefPubMed
8.
Arai T, Miyoshi Y, Kim SJ, et al. Association of GSTP1 expression with resistance to docetaxel and paclitaxel in human breast cancers. J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2008;34:734–8.CrossRef
9.
Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:253–65.CrossRefPubMed
10.
Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res. 1997;57:229–33.PubMed
11.
Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 1996;56:1253–5.PubMed
12.
McDonnell TJ, Navone NM, Troncoso P, et al. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol. 1997;157:569–74.CrossRefPubMed
13.
Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004;25:276–308.CrossRefPubMed
14.
Zhu ML, Horbinski CM, Garzotto M, et al. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 2010;70:7992–8002.CrossRefPubMedPubMedCentral
15.
Darshan MS, Loftus MS, Thadani-Mulero M, et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 2011;71:6019–29.CrossRefPubMedPubMedCentral
16.
de Leeuw R, Berman-Booty LD, Schiewer MJ, et al. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer. Clin Cancer Res: Official J Am Assoc Cancer Res. 2015;21:795–807.CrossRef
17.
Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: Preliminary results. Semin Oncol. 1999;26:14–8.PubMed
18.
Berry W, Dakhil S, Gregurich MA, et al. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol. 2001;28:8–15.CrossRefPubMed
19.
Beer TM, Pierce WC, Lowe BA, et al. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol: Official J Eur Soc Med Oncol/ESMO. 2001;12:1273–9.CrossRef
20.
Petrylak DP, Macarthur R, O’Connor J, et al. Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer. Semin Oncol. 1999;26:28–33.PubMed
21.
Petrylak DP, Macarthur RB, O’Connor J, et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol: Official J Am Soc Clin Oncol. 1999;17:958–67.
22.
Kreis W, Budman DR, Fetten J, et al. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol: Official J Eur Soc Med Oncol/ESMO. 1999;10:33–8.CrossRef
23.
Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20.CrossRefPubMed
24.
Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study. J Clin Oncol: Official J Am Soc Clin Oncol. 1999;17:2506–13.
25.
Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol: Official J Am Soc Clin Oncol. 1996;14:1756–64.
26.
Benson R, Hartley-Asp B. Mechanisms of action and clinical uses of estramustine. Cancer Invest. 1990;8:375–80.CrossRefPubMed
27.
Machiels JP, Mazzeo F, Clausse M, et al. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J Clin Oncol: Official J Am Soc Clin Oncol. 2008;26:5261–8.CrossRef
28.
Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.CrossRefPubMed
29.
Berthold DR, Pond GR, Roessner M, et al. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: Relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. J Clin Oncol: Official J Am Soc Clin Oncol. 2008;14:2763–7.
30.
Petrylak DP, Ankerst DP, Jiang CS, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Nat Cancer Inst. 2006;98:516–21.CrossRefPubMed
31.
Sonpavde G, Matveev V, Burke JM, et al. Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann Oncol: Official J Eur Soc Med Oncol/ESMO. 2012;23:1803–8.CrossRef
32.
Pond GR, Armstrong AJ, Wood BA, et al. Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. Eur Urol. 2012;61:363–9.CrossRefPubMedPubMedCentral
33.
Mountzios I, Bournakis E, Efstathiou E, et al. Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer. Urology. 2011;77:682–7.CrossRefPubMed
34.
Prostate cancer, androgen deprivation withdrawal and intermittent chemotherapy (PON-PC-02). Clinicaltrialsgov. [Internet], National Library of Medicine. 2010;NLM Indetifier: NCT01224405.
35.
Chien AJ, Moasser MM. Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: Intrinsic and acquired. Semin Oncol. 2008;35:S1–S14.
36.
Kawanobe T, Kogure S, Nakamura S, et al. Expression of human ABCB5 confers resistance to taxanes and anthracyclines. Biochem Biophys Res Commun. 2012;418:736–41.CrossRefPubMed
37.
Oprea-Lager DE, Bijnsdorp IV, Van Moorselaar RJ, et al. ABCC4 Decreases docetaxel and not cabazitaxel efficacy in prostate cancer cells in vitro. Anticancer Res. 2013;33:387–391.
38.
Sanchez C, Mercado A, Contreras HR, et al. Chemotherapy sensitivity recovery of prostate cancer cells by functional inhibition and knock down of multidrug resistance proteins. Prostate. 2011;71:1810–7.CrossRefPubMed
39.
Ploussard G, Terry S, Maille P, et al. Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res. 2010;70:9253–64.CrossRefPubMedPubMedCentral
40.
Martello LA, Verdier-Pinard P, Shen HJ, et al. Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an alpha-tubulin mutation. Cancer Res. 2003;63:1207–13.PubMed
41.
Thadani-Mulero M, Portella L, Sun S, et al. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res. 2014;74:2270–82.CrossRefPubMedPubMedCentral
42.
Antonarakis ES, Lu C, Luber B, et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol. 2015;1:582–91.CrossRefPubMed
43.
Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028–38.CrossRefPubMedPubMedCentral
44.
De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13:97–110.CrossRefPubMed
45.
Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704–15.CrossRefPubMedPubMedCentral
46.
Takebe N, Miele L, Harris PJ, et al. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: Clinical update. Nat Rev Clin Oncol. 2015;12:445–64.CrossRefPubMedPubMedCentral
47.
Marín-Aguilera M, Codony-Servat J, Reig Ò, et al. Epithelial-to-Mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer. Mol Cancer Ther. 2014;13:1270–84.CrossRefPubMed
48.
Zhang P, Sun Y, Ma L. ZEB1: At the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. Cell Cycle. 2015;14:481–7.CrossRefPubMedPubMedCentral
49.
Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch and hedgehog-dependent tumor-initiating cells. Cancer Cell. 2012;22:373–88.CrossRefPubMed
50.
Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: Aneuploidy and the mitotic checkpoint. Nat Rev Cancer. 2005;5:773–85.CrossRefPubMed
51.
Kyle AH, Huxham LA, Yeoman DM, et al. Limited tissue penetration of taxanes: A mechanism for resistance in solid tumors. Clin Cancer Res: Official J Am Assoc Cancer Res. 2007;13:2804–10.CrossRef
52.
Drummond DC, Meyer O, Hong K, et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999;51:691–743.PubMed
53.
van der Meel R, Vehmeijer LJ, Kok RJ, et al. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status. Adv Drug Deliv Rev. 2013;65:1284–98.CrossRefPubMed
54.
A phase 2 study to determine the safety and efficacy of BIND-014 docetaxel nanoparticles for injectable suspension, administered to patients with metastatic castration-resistant prostate cancer. Clinicaltrialsgov. [Internet], National Library of Medicine. 2015;NLM Indetifier: NCT01812746.
55.
Di Lorenzo G, Buonerba C, Faiella A, et al. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int. 2011;107:234–9.CrossRefPubMed
56.
Heck MM, Thalgott M, Retz M, et al. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer. BJU Int. 2012;110:E635–40.CrossRefPubMed
57.
Oudard S, Kramer G, Caffo O, et al. Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer. BJU Int. 2015;115:744–52.CrossRefPubMed
58.
de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet. 2010;376:1147–54.CrossRefPubMed
59.
Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a one hour infusion every three weeks in patients with advanced solid tumors. Clin Cancer Res: Official J Am Assoc Cancer Res. 2009;15:723–30.CrossRef
60.
Cabazitaxel versus docetaxel both with prednisone in patients with metastatic castration resistant prostate cancer (FIRSTANA). Clinicaltrialsgov. [Internet], National Library of Medicine. 2011;NLM Identifier: NCT01308567.
61.
Beer TM, Eilers KM, Garzotto M, et al. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. Clin Cancer Res: Official J Am Assoc Cancer Res. 2003;21:123–8.
62.
Scher HI, Jia X, Chi K, et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. Clin Cancer Res: Official J Am Assoc Cancer Res. 2011;29:2191–8.
63.
Kelly WK, Halabi S, Carducci M, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. Clin Cancer Res: Official J Am Assoc Cancer Res. 2012;30:1534–40.
64.
Tannock IF, Fizazi K, Ivanov S, et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): A phase 3, double-blind randomised trial. Lancet Oncol. 2013;14:760–8.CrossRefPubMed
65.
Petrylak DP, Vogelzang NJ, Budnik N, et al. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2015;16:417–25.CrossRefPubMed
66.
Chiao JW, Moonga BS, Yang YM, et al. Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br J Cancer. 2000;83:360–5.CrossRefPubMedPubMedCentral
67.
Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Nat Acad Sci USA. 2003;100:10954–9.CrossRefPubMedPubMedCentral
68.
Fizazi K, Higano CS, Nelson JB, et al. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol: Official J Am Soc Clin Oncol. 2013;31:1740–7.CrossRef
69.
Quinn DI, Tangen CM, Hussain M, et al. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): A randomised phase 3 trial. Lancet Oncol. 2013;14:893–900.CrossRefPubMedPubMedCentral
70.
Araujo JC, Trudel GC, Saad F, et al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): A randomised, double-blind phase 3 trial. Lancet Oncol. 2013;14:1307–16.CrossRefPubMed
71.
Arlen PM, Gulley JL, Parker C, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res: Official J Am Assoc Cancer Res. 2006;12:1260–9.CrossRef
72.
Small EDT, Gerritsen WR, Rolland F, Hoskin P, Smith DC, Parker C, Chondros D, Ma J, Hege K. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). In ASCO 2009 Genitourinary Cancer Symposium. 2009 Orlando, FL, USA.
73.
Morris MJ, Higano CS, Scher HI, et al. Effects of radium-223 dichloride (Ra-223) with docetaxel (D) versus D on prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (mets): A phase 1/2a clinical trial. ASCO Meet Abs. 2015;33:202.
74.
Sowery RD, Hadaschik BA, So AI, et al. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int. 2008;102:389–97.CrossRefPubMed
75.
Chi KN, Higano CS, Blumenstein BA, et al. Phase III SYNERGY trial: Docetaxel +/− custirsen and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and poor prognosis. ASCO Meet Abs. 2015;33:5009.
76.
McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 1992;52:6940–4.PubMed
77.
Sternberg CN, Dumez H, Van Poppel H, et al. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): An EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol: Official J Eur Soc Med Oncol/ESMO. 2009;20:1264–9.CrossRef
78.
Petrylak DP, Gandhi JG, Clark WR, et al. Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer. Invest New Drugs. 2015;33:397–408.CrossRefPubMedPubMedCentral
79.
Addition of enzalutamide to first line docetaxel for castration resistant prostate cancer (CHEIRON). Clinicaltrialgov. [Internet], National Library of Medicine. 2015;NLM Identifier: NCT02453009.
80.
Porsch M, Ulrich M, Wendler JJ, et al. A randomised phase II trial comparing docetaxel plus prednisone with docetaxel plus prednisone plus low-dose cyclophosphamide in castration-resistant prostate cancer. Chemotherapy. 2014;60:129–34.CrossRefPubMed
81.
Chatta GS, Feinstein TM, Appleman LJ, et al. Oxaliplatin and docetaxel in castration-resistant prostate cancer (CRPC) patients treated with up to two prior chemotherapeutic regimens: Updated results of a phase II trial. J Clin Oncol (Meeting Abstracts) 2008;26:5148.
82.
Regan MM, O’Donnell EK, Kelly WK, et al. Efficacy of carboplatin–taxane combinations in the management of castration-resistant prostate cancer: A pooled analysis of seven prospective clinical trials. Ann Oncol. 2010;21:312–8.CrossRefPubMedPubMedCentral
83.
Ross RW, Beer TM, Jacobus S, et al. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer. 2008;112:521–6.CrossRefPubMed
84.
Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737–46.CrossRefPubMedPubMedCentral
85.
Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): A randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:149–58.CrossRefPubMed
86.
James ND, Sydes MR, Mason MD, et al. Docetaxel and/or zoledronic acid for hormone-naive prostate cancer: First overall survival results from STAMPEDE (NCT00268476). ASCO Meet Abs. 2015;33:5001.
87.
Cha EK, Eastham JA. Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer. Urol Oncol. 2015;33:217–25.CrossRefPubMed
88.
Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859–66.CrossRefPubMed
89.
von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol: Official J Am Soc Clin Oncol. 2012;30:1796–804.CrossRef
90.
Surgery with or without docetaxel and leuprolide or goserelin in treating patients with high-risk localized prostate cancer. Clinicaltrialsgiv. [Internet], National Library of Medicine. 2007;NLM Identifier: NCT00430183.
91.
Schweizer MT, Huang P, Kattan MW, et al. Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): Important lessons for future trials. Cancer. 2013;119:3610–8.CrossRefPubMedPubMedCentral
92.
Sandler HM, Hu C, Rosenthal SA, et al. A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521). ASCO Meet Abs. 2015;33:LBA5002.
93.
Fizazi K, Faivre L, Lesaunier F, et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): A phase 3 randomised controlled trial. Lancet Oncol. 2015;16:787–94.CrossRefPubMed